Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
651 participants
INTERVENTIONAL
2012-05-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vehicle
Treatment with the vehicle (placebo)
Placebo Vehicle (non-treatment)
The vehicle vaginal gel in an applicator (placebo).
Product 55394
Treatment with product 55394
Product 55394
Product 55394 vaginal gel in a prefilled applicator.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Product 55394
Product 55394 vaginal gel in a prefilled applicator.
Placebo Vehicle (non-treatment)
The vehicle vaginal gel in an applicator (placebo).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Other items as identified in the protocol.
Exclusion Criteria
* Other items as identified in the protocol.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medicis Global Service Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ron Staugaard
Role: STUDY_DIRECTOR
Medicis Pharmaceutical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Phoenix, Arizona, United States
La Mesa, California, United States
Los Angeles, California, United States
San Diego, California, United States
Torrance, California, United States
Denver, Colorado, United States
Groton, Connecticut, United States
Boyton Beach, Florida, United States
Clearwater, Florida, United States
Miami, Florida, United States
North Miami, Florida, United States
Sunrise, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Roswell, Georgia, United States
Chicago, Illinois, United States
Marrero, Louisiana, United States
Falls River, Massachusetts, United States
Detroit, Michigan, United States
Saginaw, Michigan, United States
Lincoln, Nebraska, United States
Lawrenceville, New Jersey, United States
Neptune City, New Jersey, United States
Plainsboro, New Jersey, United States
Columbus, Ohio, United States
Jenkintown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Columbia, South Carolina, United States
Jackson, Tennessee, United States
Corpus Christi, Texas, United States
Houston, Texas, United States
Schertz, Texas, United States
Williston, Vermont, United States
Virginia Beach, Virginia, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP-1601-01
Identifier Type: -
Identifier Source: org_study_id